Product information and disease description
Place of product in therapy
55 evidence topics · 48 sources
Relutrigine
SCN2A- and SCN8A-related developmental and epileptic encephalopathies
- Manufacturer
- Praxis Precision Medicines
- Regulatory submission
- NDA submitted in early 2026
- Launch
- Not announced
- Last updated